Search Results

Predicting Survival in Bevacizumab-Treated Colorectal Cancer: Personalized Mathematical Models Based on Clinical and Angiogenic Biomarkers.

• Authors : Moisuc, Diana Cornelia¹ (AUTHOR); Marinca, Mihai Vasile^2,3 (AUTHOR); Gafton, Bogdan^2,3 (AUTHOR)

• Source: International Journal of Molecular Sciences. Oct2025, Vol. 26 Issue 19, p9332. 27p.

Record details

Early avastin (Bevacizumab) Administration for acute retinal vein occlusion: A key strategy for improved patient outcomes.

• Authors : Iqbal, Aamna¹ ; Zafar, Sidra²; Mukhtar, Hassam¹

• Source: Professional Medical Journal. Aug2025, Vol. 32 Issue 8, p1023-1029. 7p.

Record details

Faricimab versus bevacizumab for neovascular age-related macular degeneration: cost analysis based on real-world data from the Swedish Macula Registry

• Authors : Abdalla, Souad; Westborg, Inger; Pulkki-Brännström, Anni-Maria

Subjects: AMD; cost minimization analysis; faricimab

• Source: Acta Ophthalmologica. 103(1):99-108

Record details

Bevacizumab in frontline chemotherapy improved the survival outcome for advanced ovarian clear cell carcinoma: a multicenter retrospective analysis.

• Authors : Tate, Shinichi¹ ; Seki, Toshiyuki²; Nishikimi, Kyoko¹

• Source: Journal of Gynecologic Oncology. Sep2025, Vol. 36 Issue 5, p1-13. 13p.

Record details

Comparative analysis of bevacizumab and sorafenib on the survival of retinal ganglion cells in the treatment of retinal diseases.

• Authors : Choi, Wungrak¹ (AUTHOR); Choi, Jin-Ok¹ (AUTHOR); Chae, Min Kyung¹ (AUTHOR)

• Source: Scientific Reports. 8/5/2025, Vol. 15 Issue 1, p1-18. 18p.

Record details

Bevacizumab in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Risk-Stratified Analysis.

• Authors : Öner, İrem¹ (AUTHOR) ; Karaçin, Pınar² (AUTHOR)

• Source: Pharmaceuticals (14248247). Jun2025, Vol. 18 Issue 6, p850. 17p.

Record details

Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study

• Authors : Li, Rong-Rong; Zhou, Hui-Jun; Zeng, De-Yu

Subjects: Colorectal cancer (CRC); trifluridine/tipiracil (TAS-102); bevacizumab (BEV)

• Source: Journal of Gastrointestinal Oncology. 15(2):612-629

Record details

Exceptional Response in a Patient with mRCC Through Precision-Guided Treatment Involving Immunotherapy Rechallenge with Temsirolimus and Bevacizumab.

• Authors : Adibi, Ashkan^1,2,3; Tokat, Ünal Metin^1,2,3,4,5; Aydın, Esranur¹

• Source: Journal of Immunotherapy & Precision Oncology. May2025, Vol. 8 Issue 2, p184-190. 7p.

Record details

Efficacy of Adding Immune Checkpoint Inhibitors to Chemotherapy Plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials.

• Authors : Ando, Fumihiko^1,2 (AUTHOR); Matsuda, Akihisa² (AUTHOR) ; Miyamoto, Yuji³ (AUTHOR)

• Source: Cancers. Aug2025, Vol. 17 Issue 15, p2538. 13p.

Record details

Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial.

• Authors : Shi, Huiyang¹ (AUTHOR); Wang, Miaohan¹ (AUTHOR); Li, Junling¹ (AUTHOR)

• Source: Thoracic Cancer. Aug2025, Vol. 16 Issue 15, p1-11. 11p.

Record details